skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 996  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Database: PubMed Central remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB
Material Type:
Article 		Add to My Research

OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.33-34 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1568

Full text available

Citations Cited by
2
POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMAB: POST-HOC ANALYSIS OF SAPHYR TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA
POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMAB: POST-HOC ANALYSIS OF SAPHYR TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA
Material Type:
Article 		Add to My Research

POS0715 SUSTAINED REMISSION FROM WEEKS 16 TO 52 AND WEEKS 24 TO 52 IN PATIENTS TREATED WITH SARILUMAB: POST-HOC ANALYSIS OF SAPHYR TRIAL IN PATIENTS WITH POLYMYALGIA RHEUMATICA

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.644-645 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1989

Full text available

Citations Cited by
3
AB0478 FRENCH REAL-LIFE DATA ON THE 18-MONTH EFFECTIVENESS OF TOFACITINIB ACCORDING TO CONCOMITANT USE OF CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM RESULTS OF THE OBSERVATIONAL STUDY, DEFACTO
AB0478 FRENCH REAL-LIFE DATA ON THE 18-MONTH EFFECTIVENESS OF TOFACITINIB ACCORDING TO CONCOMITANT USE OF CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM RESULTS OF THE OBSERVATIONAL STUDY, DEFACTO
Material Type:
Article 		Add to My Research

AB0478 FRENCH REAL-LIFE DATA ON THE 18-MONTH EFFECTIVENESS OF TOFACITINIB ACCORDING TO CONCOMITANT USE OF CSDMARD IN PATIENTS WITH RHEUMATOID ARTHRITIS: INTERIM RESULTS OF THE OBSERVATIONAL STUDY, DEFACTO

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1432-1432 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.4187

Full text available

Citations Cited by
4
AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS
AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS
Material Type:
Article 		Add to My Research

AB0539 IXEKIZUMAB TREATMENT RESPONSE: CONSISTENCY OVER TIME AND AT EACH VISIT IN PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1301-1302 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.1514

Full text available

Citations Cited by
5
AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING
AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING
Material Type:
Article 		Add to My Research

AB0207 ANALYSIS OF ABATACEPT TREATMENT RETENTION AND EFFICACY ACCORDING TO DISEASE DURATION AND TREATMENT LINE IN A REAL-WORLD SETTING

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.1128-1130 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.955

Full text available

Citations Cited by
6
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY
POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY
Material Type:
Article 		Add to My Research

POS0599 DISEASE ACTIVITY IN PATIENTS WITH RA BY SEROSTATUS AND TREATMENT LINE, FOLLOWING TREATMENT WITH ABATACEPT: RESULTS FROM AN INTERNATIONAL OBSERVATIONAL STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.533-534 [Peer Reviewed Journal]

2021 Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2021-eular.928

Full text available

Citations Cited by
7
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
Material Type:
Article 		Add to My Research

SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.951 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.6746

Full text available

Citations Cited by
8
SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
Material Type:
Article 		Add to My Research

SAT0253 Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.988 [Peer Reviewed Journal]

2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;Copyright: 2018 © 2018, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-eular.2000

Full text available

Citations Cited by
9
AB1118 EFFECT OF APREMILAST ON PSORIATIC DISEASE DOMAINS STRATIFIED BY EXTENT OF SKIN INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
AB1118 EFFECT OF APREMILAST ON PSORIATIC DISEASE DOMAINS STRATIFIED BY EXTENT OF SKIN INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
Material Type:
Article 		Add to My Research

AB1118 EFFECT OF APREMILAST ON PSORIATIC DISEASE DOMAINS STRATIFIED BY EXTENT OF SKIN INVOLVEMENT IN PATIENTS WITH PSORIATIC ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1788-1789 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1583

Full text available

Citations Cited by
10
POS1501 LUPUSNET – A FEDERATED MODEL/NETWORK TO SUPPORT REAL-WORLD DATA RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS
POS1501 LUPUSNET – A FEDERATED MODEL/NETWORK TO SUPPORT REAL-WORLD DATA RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS
Material Type:
Article 		Add to My Research

POS1501 LUPUSNET – A FEDERATED MODEL/NETWORK TO SUPPORT REAL-WORLD DATA RESEARCH IN SYSTEMIC LUPUS ERYTHEMATOSUS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1108-1108 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3017

Full text available

Citations Cited by
11
POS0834 LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF NEUROIMMUNE MODULATION USING A VAGUS NERVE STIMULATION DEVICE IN PATIENTS WITH RHEUMATOID ARTHRITIS
POS0834 LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF NEUROIMMUNE MODULATION USING A VAGUS NERVE STIMULATION DEVICE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Material Type:
Article 		Add to My Research

POS0834 LONG-TERM EXTENSION STUDY OF THE SAFETY AND EFFICACY OF NEUROIMMUNE MODULATION USING A VAGUS NERVE STIMULATION DEVICE IN PATIENTS WITH RHEUMATOID ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.714-714 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.5037

Full text available

Citations Cited by
12
POS1349 A BIOMARKER APPROACH TO DATA-DRIVEN IDENTIFICATION OF ENDOTYPES IN KNEE OA PATIENTS
POS1349 A BIOMARKER APPROACH TO DATA-DRIVEN IDENTIFICATION OF ENDOTYPES IN KNEE OA PATIENTS
Material Type:
Article 		Add to My Research

POS1349 A BIOMARKER APPROACH TO DATA-DRIVEN IDENTIFICATION OF ENDOTYPES IN KNEE OA PATIENTS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1026-1026 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3433

Full text available

Citations Cited by
13
POS1365 STRUCTURAL SEVERITY IN KNEE OSTEOARTHRITIS IMPACTS TREATMENT RESPONSE: A POST HOC POOLED ANALYSIS OF LORECIVIVINT CLINICAL TRIALS
POS1365 STRUCTURAL SEVERITY IN KNEE OSTEOARTHRITIS IMPACTS TREATMENT RESPONSE: A POST HOC POOLED ANALYSIS OF LORECIVIVINT CLINICAL TRIALS
Material Type:
Article 		Add to My Research

POS1365 STRUCTURAL SEVERITY IN KNEE OSTEOARTHRITIS IMPACTS TREATMENT RESPONSE: A POST HOC POOLED ANALYSIS OF LORECIVIVINT CLINICAL TRIALS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1035-1035 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2791

Full text available

Citations Cited by
14
POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS
Material Type:
Article 		Add to My Research

POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.666-667 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3883

Full text available

Citations Cited by
15
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME
Material Type:
Article 		Add to My Research

POS1118 DISCRIMINATING CAPACITY OF THE ASAS HEALTH INDEX IN PATIENTS TREATED WITH IXEKIZUMAB IN THE COAST PROGRAMME

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.884-885 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.82

Full text available

Citations Cited by
16
OP0074 RADIOGRAPHIC AND PAIN OUTCOMES FROM A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY AND EFFICACY OF LORECIVIVINT IN SUBJECTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE (OA-07): SINGLE BLIND AND CROSSOVER RESULTS
OP0074 RADIOGRAPHIC AND PAIN OUTCOMES FROM A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY AND EFFICACY OF LORECIVIVINT IN SUBJECTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE (OA-07): SINGLE BLIND AND CROSSOVER RESULTS
Material Type:
Article 		Add to My Research

OP0074 RADIOGRAPHIC AND PAIN OUTCOMES FROM A PHASE 3 EXTENSION STUDY EVALUATING THE SAFETY AND EFFICACY OF LORECIVIVINT IN SUBJECTS WITH SEVERE OSTEOARTHRITIS OF THE KNEE (OA-07): SINGLE BLIND AND CROSSOVER RESULTS

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.50-51 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2833

Full text available

Citations Cited by
17
POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
Material Type:
Article 		Add to My Research

POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1133-1134 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.1694

Full text available

Citations Cited by
18
POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT
Material Type:
Article 		Add to My Research

POS1543 EFFICACY OF RISANKIZUMAB IN THE TREATMENT OF PsA PATIENTS WITH LIMITED AND EXTENSIVE JOINT INVOLVEMENT

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.1139-1140 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3273

Full text available

Citations Cited by
19
OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Material Type:
Article 		Add to My Research

OP0139 EFFICACY AND SAFETY OF ABBV-599 HIGH DOSE (ELSUBRUTINIB 60 MG AND UPADACITINIB 30 MG) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.91-92 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.2402

Full text available

Citations Cited by
20
POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL
POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL
Material Type:
Article 		Add to My Research

POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL

Annals of the rheumatic diseases, 2023-06, Vol.82 (Suppl 1), p.379-380 [Peer Reviewed Journal]

2023 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2023-eular.3679

Full text available

Citations Cited by

Results 1 - 20 of 996  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 2001  (10)
  2. 2001 To 2005  (13)
  3. 2006 To 2011  (22)
  4. 2012 To 2017  (284)
  5. After 2017  (668)
  6. More options open sub menu

Resource Type 

  1. Articles  (995)
  2. Reviews  (1)
  3. More options open sub menu

Language 

  1. Japanese  (18)
  2. Portuguese  (1)
  3. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait